Advertisement

On the Antihypertensive Properties of Nitrendipine, with Observations of Its Effects on Electrolyte Excretion

  • C. E. Hall
  • S. Hungerford
Conference paper
Part of the Bayer-Symposium book series (BAYER-SYMP, volume 9)

Summary

The weekly implantation of 25 mg nitrendipine pellets effectively prevented spontaneous and DOC-salt hypertension and were well tolerated. In the latter model steroid-induced “diabetes insipidus-like” syndrome was also prevented.

Nitrendipine acted differently in rats with spontaneous hypothalamic diabetes insipidus than it did in normal Long-Evans rats. When 0.7% NaCl was used as the loading solution, the latter responded with polyuria, lowered urine osmolality, natriuresis and kaliuresis, none of which occurred in DI rats. When the loading solution consisted of 0.45% NaCl + 0.25% KCl, nitrendipine caused polyuria in normal rats, without any effect on electrolyte excretion, and decreased electrolyte excretion without affecting urine volume in DI rats.

When loading solutions of 0.9% NaCl, 0.9% KCl and 5.1% glucose were used, the response to nitrendipine was again different. In the first instance the drug caused polyuria, hypernatremia and hyperkalemia without affecting urine osmolality: in the second it had no effect, and in the third it caused hyponatremia. When dual solute solutions of NaCl + glucose, NaCl + KCl, or KCl + glucose were used, there were still different responses. With the first, nitrendipine reduced urinary Na+ and K+, with the second it also reduced urine volume, and with the third it increased urine output while diminishing urine osmolality and K+ excretion.

Keywords

Urine Volume Urine Osmolality Electrolyte Excretion Urine Composition Antihypertensive Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hiwatani M, Taira N (1979) Antihypertensive effect of niludipine (Bay a 7168) on conscious renal hypertensive dogs. Arzneim Forsch 29:1373–1376.Google Scholar
  2. 2.
    Kazda S, Garthoff B, Dycka J, Iwai J (1982) Prevention of malignant hypertension in salt-loaded “S” Dahl rats with the calcium antagonist nifedipine. Clin Exper Hyper 44:1231–1241.CrossRefGoogle Scholar
  3. 3.
    Fleckenstein A, Fleckenstein-Grün G (1980) Cardiovascular protection by Ca antagonists. Eur Heart J 1(Suppl B): 15–21.PubMedGoogle Scholar
  4. 4.
    Hall CE, Hungerford S (1983) Prevention of spontaneous and glucocorticoid hypertension in rats by nisoldipine. Physiol Behav 30:899–903.PubMedCrossRefGoogle Scholar
  5. 5.
    Hansson L, Andrén L, Orö L, Rymen T (1983) Pharmacokinetic and pharmacodynamic parameters in patients treated with nitrendipine. Hypertension 5(Part 2):25–28.Google Scholar
  6. 6.
    Guazzi M, Olivari MT, Polese A, Fiorentini C, Magrini F, Moruzzi P (1979) Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther 22:528–532.Google Scholar
  7. 7.
    Lewis GRJ, Morley KD, Lewis BM, Bones PJ (1978) The treatment of hypertension with verapamil. N Z Med J 87:351–354.PubMedGoogle Scholar
  8. 8.
    Leary WP, Asmal AC (1979) Treatment of hypertension with verpamil. Curr Ther Res 25:747–752.Google Scholar
  9. 9.
    Garthoff B, Kazda S, Knorr A (1982) Nitrendipine increases sodium excretion in acutely saline loaded rats. Biochem Pharmacol 31:3015–3016.PubMedCrossRefGoogle Scholar
  10. 10.
    DiBona GF, Sawin LL (1984) Renal tubular site of action of felodipine. J Pharmacol Exp Ther 228:420–424.PubMedGoogle Scholar
  11. 11.
    Morita H, Nasao T, Yabana H, Yamaguchi I (1983) Hypertensive and diuretic action of diltiazem in spontaneously hypertensive and Wistar-Kyoto rats. J Pharmacol Exp Ther 227:472–477.Google Scholar
  12. 12.
    Gomez-Sanchez CE, Holland OB, Higgins JR, Mathieu R, Gruber M, Kaplan NM (1976) Mineralocorticoid activity of 16 β hydroxy-dehydroepiandrosterone and related steroids. J Lab Clin Med 88:571–577.PubMedGoogle Scholar
  13. 13.
    Hall CE, Gomez-Sanchez CE, Hungerford S, Gomez-Sanches EP (1981) Mineralocorticoid and hypertensive properties of 19-nor progesterone. Endocrinology 109:1168–1175.PubMedCrossRefGoogle Scholar
  14. 14.
    Hall CE, Hungerford S (1982) Inhibition of DOC-salt and adrenal-regeneration hypertension with the calcium blocker nifedipine. Clin Exper Hypertension 4:1217–1230.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • C. E. Hall
  • S. Hungerford

There are no affiliations available

Personalised recommendations